Congenital myotonic dystrophy
Congenital Myotonic Dystrophy is a type of neuromuscular disorder that is present from birth. It is a subtype of Myotonic Dystrophy, a genetic disorder characterized by progressive muscle wasting and weakness.
Overview[edit | edit source]
Congenital Myotonic Dystrophy is caused by a mutation in the DMPK (Dystrophia Myotonica-Protein Kinase) gene. This gene mutation leads to the production of an abnormal version of the DMPK protein, which interferes with the normal functioning of muscle cells and other types of cells in the body. The disorder is inherited in an autosomal dominant manner, meaning that an affected person has a 50% chance of passing the disorder to each of their children.
Symptoms[edit | edit source]
The symptoms of Congenital Myotonic Dystrophy can vary widely in severity, but they typically include muscle weakness and wasting, myotonia (a condition in which the muscles are unable to relax after contraction), and developmental delays. Other symptoms can include intellectual disability, difficulties with speech and swallowing, and problems with the heart, lungs, and digestive system.
Diagnosis[edit | edit source]
The diagnosis of Congenital Myotonic Dystrophy is typically made based on the presence of characteristic clinical symptoms, a family history of the disorder, and genetic testing. The genetic test involves analyzing a sample of blood to look for the abnormal DMPK gene.
Treatment[edit | edit source]
There is currently no cure for Congenital Myotonic Dystrophy, and treatment is focused on managing the symptoms of the disorder. This can include physical therapy to improve muscle strength and flexibility, speech therapy to address difficulties with speech and swallowing, and medications to manage symptoms such as myotonia.
Research[edit | edit source]
Research into Congenital Myotonic Dystrophy is ongoing, with scientists working to better understand the genetic basis of the disorder and to develop new treatments. Current areas of research include studying the role of the DMPK protein in the body and investigating potential drug treatments that could target the abnormal DMPK gene.
See Also[edit | edit source]
This neuromuscular disorder related article is a stub. You can help WikiMD by expanding it.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
